pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 105

Chemotherapy Immunization FDA 105

pharmaphorum

AUGUST 22, 2021

Bristol-Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer therapy, getting FDA approval for the drug for post-surgical treatment of invasive bladder cancer. ” The post BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapy appeared first on.

FDA 78

FDA Chemotherapy Immunization 78

pharmaphorum

SEPTEMBER 13, 2022

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.

Chemotherapy 98

Chemotherapy Immunization FDA Documentation 98

Pharmafile

JANUARY 27, 2023

The FDA has revoked its approval of AstraZeneca’s Evusheld due to the fact that it is not effective against more than 90% of COVID-19 variants currently in circulation in the US. read more

FDA 52

FDA Chemotherapy Immunization Communication 52

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

FDA 52

FDA Chemotherapy Labelling Immunization 52

pharmaphorum

JULY 2, 2021

The decision comes after FDA advisors voted six to two in April that Keytruda (pembrolizumab) should not stay on the market as a treatment option for patients with PD-L1-expressing gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have received two or more earlier lines of therapy.

FDA 52

FDA Chemotherapy Immunization 52

pharmaphorum

DECEMBER 1, 2021

BeyondSpring’s hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company’s lead drug plinabulin as a treatment for low white blood cell counts caused by cancer chemotherapy. of patients taking plinabulin plus pegfilgrastim and 13.6%

FDA 52

FDA Chemotherapy Immunization 52

European Pharmaceutical Review

APRIL 10, 2024

The recent FDA approvals of two microbiome products in the US, in November 2022 and April 2023, 1-2 represent a significant milestone, maturing the industry and paving the way for advancement and regulatory clearance of additional microbiome products in broader indications. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Chemotherapy FDA Pharmaceutical Companies 95

Pharmaceutical Technology

APRIL 26, 2023

The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM). This marks the first-ever designation for genetically modified gamma-delta T cell therapies.

FDA 52

FDA Chemotherapy Immunization 52

Pharmaceutical Technology

FEBRUARY 26, 2023

While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. In November 2022, Ferring Pharmaceuticals’s Rebyota became the first FDA-approved microbiome-based therapeutic to treat recurrent CDI. But the approval came through after an FDA Advisory Committee meeting. with placebo.

FDA 111

FDA Immunization Chemotherapy 111

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines 98

Vaccines FDA Immunization Chemotherapy 98

European Pharmaceutical Review

JUNE 27, 2023

Of note, the US Food and Drug Administration (FDA) and ANSM (French regulatory authorities) have established themselves as early leaders to develop guidelines. Since these fresh FDA approvals for microbiome-based therapies, regulatory pathways are becoming clearer and opening new perspectives for companies.

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

pharmaphorum

MARCH 30, 2022

The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.

Chemotherapy 97

Chemotherapy Immunization FDA 97

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents.

Immunization 105

Immunization Chemotherapy Compounding FDA 105

European Pharmaceutical Review

OCTOBER 19, 2023

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. What do you envision the future of radiopharmaceuticals to be like?

Chemotherapy 105

Chemotherapy Compounding Immunization FDA 105

The Checkup by Singlecare

SEPTEMBER 12, 2023

The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California. This is a typical immunization response as your body builds a defense against possible infection.

Vaccines 105

Vaccines Immunization Pharmacy Program Director Chemotherapy 105

pharmaphorum

NOVEMBER 29, 2022

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blockings its interactions with both PD-1 and B7.1 Patients given the Tecentriq plus chemotherapy combination survived a median of 16 months after treatment, compared with 13.4

Chemotherapy 52

Chemotherapy FDA Immunization 52

pharmaphorum

DECEMBER 21, 2020

Trodelvy (sacituzumab govitecan) is a first-in-class TROP2 antibody-drug conjugate drug that was granted accelerated approval by the FDA in April for adults with metastatic triple-negative breast cancer (TNBC), who have received at least two previous therapies for metastatic disease. months in patients treated with chemotherapy.

Chemotherapy 126

Chemotherapy Immunization FDA 126

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

pharmaphorum

DECEMBER 18, 2020

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data gathered so far in advanced disease. The median progression-free survival (PFS) of patients treated with Margenza and chemotherapy was 5.8

Chemotherapy 52

Chemotherapy FDA Immunization 52

pharmaphorum

NOVEMBER 23, 2020

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin’s lymphoma. The post FDA sets May date for verdict on ADC’s lymphoma drug Lonca appeared first on.

FDA 52

FDA Chemotherapy Immunization 52

European Pharmaceutical Review

MAY 23, 2024

Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. 2 Why does CARVYKTI have potential in multiple myeloma?

Medical Schools 110

Medical Schools FDA Chemotherapy Immunization 110

European Pharmaceutical Review

FEBRUARY 15, 2023

Only one late-onset immune-related adverse event (AE) occurred, 16 months post-treatment. Neoadjuvant nivolumab in combination with chemotherapy was approved by the US Food and Drug Administration (FDA) in March 2022 for lung cancer. Neoadjuvant nivolumab did not lead to surgical delays.

Chemotherapy 98

Chemotherapy Immunization FDA 98

pharmaphorum

MAY 24, 2021

While there are plenty of EGFR-targeting drugs on the market for NSCLC, Rybrevant is the first to be FDA-approved for patients with exon 20 mutations, and also represents Janssen’s first lung cancer therapy. It is in trials as both a first-line and second-line therapy after chemotherapy for tis type of cancer.

FDA 52

FDA Chemotherapy Immunization 52

pharmaphorum

DECEMBER 10, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The combination earned a breakthrough designation from the FDA earlier this year.

Chemotherapy 72

Chemotherapy FDA Immunization 72

pharmaphorum

JANUARY 5, 2021

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

pharmaphorum

JANUARY 26, 2023

The cancer is particularly challenging for immunotherapy, as it tends to have fewer mutations than other cancers, presenting fewer targets for immune cells, and tends to be immunologically ‘cold’, with few immune cells infiltrating the tumour. It remains ongoing with updated results due in the coming months.

Chemotherapy 59

Chemotherapy Immunization FDA 59

The Checkup by Singlecare

OCTOBER 24, 2024

As an immune checkpoint inhibitor, pembrolizumab prevents cancer cells from blocking the immune system’s ability to kill off cancer cells. The FDA has conditionally approved the use of gilvetmab in dogs with stage 2 or stage 3 melanoma or stage 1, stage 2, or stage 3 mast cell tumors. What is Keytruda used for in dogs?

Immunization 52

Immunization Chemotherapy FDA Dosage 52

pharmaphorum

OCTOBER 14, 2021

The FDA has approved Merck’s Keytruda as a first-line therapy for advanced cervical cancer. Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1.

Chemotherapy 45

Chemotherapy Research Laboratories Immunization FDA 45

pharmaphorum

JULY 1, 2022

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory. The post AZ takes aim at BMS’ lead in neoadjuvant NSCLC appeared first on.

Chemotherapy 52

Chemotherapy FDA Immunization 52

pharmaphorum

NOVEMBER 20, 2020

months for patients in the control group, who received standard second-line chemotherapy. The green light made it the first and only targeted, chemo-free regimen licensed in Europe specifically for patients with BRAF V600E-positive mCRC, and came shortly after the combination was approved by the FDA for the same indication.

Chemotherapy 52

Chemotherapy Immunization FDA 52

pharmaphorum

JANUARY 26, 2022

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences’ magrolimab, the centre piece of its $4.9 Other research suggests it my also play downgrade immune responses by cell-killing T cells as well as dendritic cells, which are involved in antibody responses, making it a compelling target for drug developers.

FDA 40

FDA Adverse Reactions Chemotherapy Immunization 40

Pharmaceutical Technology

AUGUST 16, 2022

months compared with patients treated with standard-of-care chemotherapy. The accelerated US Food and Drug Administration (FDA) approval of Enhertu for HER2-mutant NSCLC was based on the findings of the Phase II DESTINY-Lung02 trial, which demonstrated an impressive 57.7%

Chemotherapy 59

Chemotherapy Immunization FDA 59

The Checkup by Singlecare

OCTOBER 8, 2024

Ozempic (semaglutide) is a weekly prescription medication that is approved by the Food and Drug Administration (FDA) to help control blood glucose levels in people with Type 2 diabetes. It is also sometimes prescribed off-label (for a non-FDA-approved use) for weight loss.

Immunization 52

Immunization Chemotherapy FDA Labelling 52

Pharmaceutical Technology

JULY 8, 2022

Moreover, a deeper understanding of immune evasion by cancer cells may provide novel sensitization strategies to further enhance the clinical response of BiTEs. . The confirmatory Phase III TOWER trial demonstrated superior overall survival in R/R B-ALL patients with Blincyto versus conventional chemotherapy (7.7 months vs. 4.0

Chemotherapy 59

Chemotherapy Immunization FDA 59

pharmaphorum

OCTOBER 4, 2021

Xencor has previously partnered with MorphoSys and Incyte to test plamotamab in combination with their CD19-targeted antibody Monjuvi (tafasitamab) – plus Bristol-Myers Squibb’s Revlimid (lenalidomide) – as a chemotherapy-free strategy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive type of NHL.

Chemotherapy 52

Chemotherapy Immunization FDA 52

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. Car-t “The living drugs”, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy.

Adverse Reactions 104

Adverse Reactions Immunization Medical Schools Chemotherapy 104